- Company
- Kukje Pharm and Celltrion will comarket Eylea biosimilar
- by Nho, Byung Chul Apr 3, 2024 05:50am
- By taking in Celltrion's Eylea biosimilar, Kukje Pharm has further strengthened its position in the domestic ophthalmic disease treatment market. On the 2nd, Kukje Pharm announced that it has entered into a strategic marketing partnership agreement with Celltrion to commercialize CT-P42 (Eylea biosimilar, aflibercept), an ophthalmic ret
- Policy
- Novartis’ 'Ilaris' will be reconsidered for the DREC review
- by Lee, Tak-Sun Apr 3, 2024 05:50am
- The rare disease drug 'Ilaris Injection (canakinumab, Novartis Korea)' will be reconsidered for review by the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA) after two months. Ilaris is a drug used to treat a rare disease called 'periodic fever syndromes (PFS)' for which there
- Company
- K-Bio accelerates solid cancer trials with ‘new MOA’ CAR-T
- by Son, Hyung-Min Apr 2, 2024 05:54am
- The Korean pharmaceutical and biotechnology industry aim to introduce solid cancer-targeting CAR-T with new mechanisms of action (MOA). Chimeric antigen receptor T (CAR-T) cell therapy is an immune cell therapy for cancer treatment designed to deliver genetic material to T cells to produce the CAR in patients. CAR-T has not been approved for
- Policy
- 3 more successful Zolgensma treatment cases reported…
- by Lee, Tak-Sun Apr 2, 2024 05:54am
- Zolgensma, a one-shot treatment for spinal muscular atrophy (SMA), is demonstrating a high effect post-reimbursement. The government has been conducting a post-marketing performance evaluation on the drug since its reimbursement in August 2022, and so far, there has been only 1 case of failure reported after its use. The drug costs a
- Policy
- Oppo parties also promise 'drug price system reform'
- by Lee, Jeong-Hwan Apr 2, 2024 05:54am
- Following the ruling party’s pledge, the opposition parties also announced their general election pledges to promote Korea’s growth into a pharma-bio powerhouse, by investing in research and development (R&D) and preparing customized drug pricing systems for the global entry of Korea’s new drugs, heralding their intent to foster and devel
- Company
- PharmaEssentia reattempts reimb of BESREMi in Korea
- by Eo, Yun-Ho Apr 2, 2024 05:53am
- PharmaEssentia is again attempting to list BESREMi, its new drug for polycythemia vera (PV), for reimbursement in Korea. Dailypharm’s coverage found that the Taiwanese pharmaceutical company PharmaEssentia has recently resubmitted an application for the reimbursement of BESREMi (Ropeginterferon alfa-2b) in Korea. The company had submi
- Policy
- Price reduction dilemma for 'Forxiga' set for withdrawal
- by Lee, Tak-Sun Apr 2, 2024 05:53am
- 'Forxiga tab (dapagliflozin, AstraZeneca),' a diabetes treatment that was announced to be withdrawn from the Korean market in the second quarter of this year, has failed to reach an agreement in the price-volume agreement (PVA). Initial negotiations fell apart, so the company is likely to attempt renegotiation. The company hopes to maint
- Policy
- K-drugs’ approval in the Philippines to be expedited
- by Lee, Tak-Sun Apr 1, 2024 05:29am
- The Philippine Food and Drug Administration (PH-FDA) has newly listed Korea’s Ministry of Food and Drug Safety as a Reference Drug Regulatory Agency, which is expected to shorten the approval process of domestic drugs that are exported to the Philippines. The MFDS announced that it has been listed as a Reference Drug Regulatory Agency by
- Company
- Oral option introduced for psoriasis in Korea
- by Eo, Yun-Ho Apr 1, 2024 05:29am
- Oral treatment options are trending in the field of psoriasis. Therefore, It remains to be seen whether the market, which is currently dominated by biologic drugs, will shift in the future. The frontrunner in the field is BMS Pharmaceutical Korea's TYK2 inhibitor Sotyktu (deucravacitinib). The drug, which is a treatment for plaque psoriasi
- Opinion
- [Reporter’s View] Results needed for ‘Ilaris’ on hold
- by Eo, Yun-Ho Apr 1, 2024 05:29am
- It made its third attempt, but Ilaris faced another challenge. ‘Ilaris,’ a drug for about ten patients in South Korea, has not cleared the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA) and is on hold. Novartis Korea’s Ilaris (canakinumab), a drug used to treat periodic fever
